ArticleJournal of neurosurgery. Case lessons2026
Intravenous cangrelor as rescue therapy for acute thrombosis in neuroendovascular procedures: illustrative cases.
Article in Journal of neurosurgery. Case lessons, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClot formation can lead to serious complications associated with endovascular procedures. Cangrelor, a novel intravenous (IV) antiplatelet medication, has been FDA approved for percutaneous coronary intervention. However, the use of cangrelor for the purpose of rescue therapy in neurovascular procedures has not been established. OBSERVATIONS: At the authors' institution, 4 patients received IV cangrelor for emergency thrombolysis during cerebral aneurysm embolization. In 3 cases, thrombus resolution was observed within minutes of cangrelor administration, restoring normal flow. In 1 case, cangrelor facilitated partial thrombolysis in conjuction with mechanical thrombectomy. No patient experienced an ischemic stroke or hemorrhagic complication. All patients were discharged home at their neurological baseline. Follow-up demonstrated no recurrent thrombosis or aneurysm recurrence. LESSONS: In this limited series, cangrelor was found to be a safe and effective IV platelet inhibitor with emergency thrombolysis capability after cerebral aneurysm embolization. Cangrelor is an attractive rescue agent due to its rapid onset, reversible P2Y12 inhibition, and extremely short half-life (on/off effect). https://thejns.org/doi/10.3171/CASE25930.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.